Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19 — MINECRAFT  

COVID-19 Acute Respiratory Distress Syndrome Clinical Trial

Official title: MINECRAFT Study: MINEralcorticoid Receptor Antagonism With CanRenone As eFfective Treatment in Moderate to Severe ARDS in COVID-19, a Phase 2 Clinical Trial.

Status Not yet recruiting

Clinical Trial Summary

The main aim of the study is to estimate the potential efficacy of i.v. canrenone as add-on therapy on maximal medical treatment versus maximal medical treatment alone in treating moderate-to-severe ARDS due to SARS-CoV-2.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Acute Lung Injury
• COVID-19
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn

• NCT number: NCT04977960
• Study type: Interventional
• Source: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
• Contact: Marco Vicenzi, MD
• Phone: +390255033537
• Email: marco.vicenzi@policlinico.mi.it
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: September 2022
• Completion date: December 2023